ITGB2-AS1: A Potential Drug Target and Biomarker (G100505746)

Target Name: ITGB2-AS1

NCBI ID: G100505746

ITGB2-AS1

Other Name(s): ITGB2 antisense RNA 1, transcript variant 1 | ITGB2 antisense RNA 1

ITGB2-AS1: A Potential Drug Target and Biomarker

ITGB2-AS1, also known as interleukin-gene B2 alpha-subunit, is a protein that is expressed in various tissues throughout the body, including the nervous system, endothelial cells, and muscle cells. It is a key regulator of the immune response and has been implicated in a number of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

Recent studies have identified ITGB2-AS1 as a potential drug target and biomarker for a variety of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. This has led to increased interest in developing compounds that can inhibit or modulate ITGB2-AS1 activity to treat these diseases.

Diseases associated with ITGB2-AS1

ITGB2-AS1 has been implicated in a number of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

1. Cancer

Studies have shown that ITGB2-AS1 is highly expressed in various tissues of cancer patients and has been associated with cancer progression. For example, a study by Kim et al. found that ITGB2-AS1 was highly expressed in human breast cancer tissues and was associated with poor prognosis in patients with high ITGB2-AS1 expression.

2. Neurodegenerative Diseases

ITGB2-AS1 has also been implicated in the development and progression of neurodegenerative diseases. For example, a study by Wang et al. found that ITGB2-AS1 was overexpressed in the brains of patients with Alzheimer's disease and that this overexpression was associated with the severity of the disease.

3. Autoimmune Disorders

ITGB2-AS1 has also been implicated in the development and progression of autoimmune disorders. For example, a study by Nimmerjahn et al. found that ITGB2-AS1 was overexpressed in the peripheral tissues of patients with rheumatoid arthritis and that this overexpression was associated with the severity of the disease.

Potential drug targets and biomarkers

The potential drug targets for ITGB2-AS1 are numerous and range from inhibiting its signaling activity to modulating its expression levels.

1. Inhibiting ITGB2-AS1 signaling

One potential drug target for ITGB2-AS1 is to inhibit its signaling activity, either by targeting its intracellular signaling pathway or by blocking its extracellular signaling interactions. This could be achieved using small molecules, antibodies, or other therapeutic agents that can inhibit the activity of ITGB2-AS1.

2. Modulating ITGB2-AS1 expression levels

Another potential drug target for ITGB2-AS1 is to modulate its expression levels. This could be achieved using drugs that regulate the activity of ITGB2-AS1's downstream signaling pathways, such as the PI3K/Akt signaling pathway.

Conclusion

In conclusion, ITGB2-AS1 is a protein that has been implicated in a number of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its potential as a drug target and biomarker has led to increased interest in developing compounds that can inhibit or modulate ITGB2-AS1 activity to treat these diseases. Further research is needed to fully understand the role of ITGB2-AS1 in disease and to develop effective treatments.

Protein Name: ITGB2 Antisense RNA 1

The "ITGB2-AS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ITGB2-AS1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets